Advanced Enzyme Technologies Limited announces a capital-allocation move

The buyback utilized 99.99% of the Board-approved maximum size: Rs 696,962,962.22 against a maximum of Rs 697,000,000, excluding transaction costs ^{[1] [2]}.

The company bought back shares at an average price of Rs 289.09 per share ^[1]. The offer-period VWAP could not be confirmed from the cited material, so the premium or discount of the buyback price versus VWAP cannot be calculated.

Pro forma, the extinguishment lifts TTM EPS by about 2.20%, or Rs 0.33 per share. ROE increases by roughly 0.5 percentage points, while promoter ownership rises by 0.95 pp to 44.19%.

Quantified impact

• Share-count reduction: 2,410,906 shares were bought back, reducing total equity shares from 111,976,150 to 109,565,244. Promoter shares remained unchanged at 48,419,485. ^[3]
• TTM EPS: Adding reported basic EPS for Q2 FY26 to Q1 FY27 gives Rs 14.82 per share, derived from Rs 3.87, Rs 3.80, Rs 3.84 and Rs 3.31. ^{[4] [5] [6] [7]}
• Post-buyback EPS: Rs 14.82 × 111,976,150 / 109,565,244 = Rs 15.15, implying an increase of Rs 0.33 per share, or 2.20%. This is a mechanical pro forma adjustment assuming TTM earnings are unchanged.
• ROE: The reported quarterly ROE values for Q2 FY26 to Q1 FY27 sum mechanically to 11.8%. ^{[8] [9] [10] [11]} Applying the buyback-related equity reduction of approximately Rs 69.70 Crores to the latest reported total equity of Rs 1,632.0 Crores gives an estimated post-buyback ROE of about 12.3%, or an improvement of approximately 0.5 pp. The buyback consideration was Rs 696,962,962.22. ^[1] Latest reported total equity was Rs 1,632.0 Crores. ^[12]

Promoter ownership

Promoter and promoter-group ownership increased from 43.24% pre-buyback to 44.19% post-buyback, a 0.95 pp increase. This was a denominator effect: promoter shares were unchanged, while the total equity base fell. Public shareholding correspondingly declined from 56.76% to 55.81%. ^[3]

Caveat: The EPS calculation is a clean share-count adjustment. The ROE figure is an estimate because a post-buyback TTM ROE using average equity was not separately reported; the approximately 0.5 pp increase should therefore be read as a mechanical pro forma impact, not a subsequently reported accounting ratio.

The current buyback was Rs 69.70 crore, with Rs 69.696 crore actually deployed to repurchase 2,410,906 shares at an average Rs 289.09 per share. The Board’s ceiling price was Rs 500 per share, so the realized price was about 57.8% of the maximum permitted price—the Rs 500 figure should not be treated as the actual buyback price. ^{[1] [2]}

FY27 buyback versus FY21

The FY21 authorization size, ceiling price, actual shares repurchased and cash deployed could not be confirmed from the cited material. Therefore, it would be unsafe to characterize the current buyback as larger, smaller, cheaper or more expensive than FY21.

Does this indicate a capital-allocation shift?

It is a meaningful shareholder-return action, but not yet evidence of a structural strategy change. The buyback is sizeable relative to the company’s disclosed reinvestment programme: management referred to a Rs 123 crore capex programme, including approximately Rs 50 crore for R&D and Rs 20 crore of normal capex. ^[13] Mechanically, the completed Rs 69.696 crore buyback ^[1] was about 1.39 times the R&D allocation and 56.7% of the total capex programme; this comparison does not establish that the buyback displaced R&D or growth spending.

The dividend evidence points to a possible broadening—not necessarily a replacement—of the payout mechanism. The FY26 annual-report summary reported a 34% dividend payout ratio, alongside a Rs 4 per-share interim dividend and a proposed Rs 1.35 final dividend. ^[14] However, the structured financial series reports a 0.0% dividend payout ratio for FY22-FY26 ^{[15] [16] [17] [18] [19]}. That inconsistency must be reconciled before drawing a reliable multi-year dividend-policy trend.

Analyst read: the buyback appears to be an additional way of returning surplus cash after funding R&D and capex, rather than clear evidence that management has abandoned reinvestment or shifted permanently away from dividends. A genuine strategy change would require evidence of a repeatable buyback policy, a stated change in dividend policy, or a sustained reduction in R&D and growth investment.